Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. - Wikidata - wikimedia - TriplyDB

Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

http://www.wikidata.org/entity/Q36692337

about

PPARs and the cardiovascular system PPAR-γ -- a possible drug target for complicated pregnancies Smooth Muscle-Targeted Overexpression of Peroxisome Proliferator Activated Receptor-γ Disrupts Vascular Wall Structure and Function Endothelial PPAR-γ Protects Against Vascular Thrombosis by Downregulating P-Selectin ExpressionSignificance Contrasting vascular effects caused by loss of Bardet-Biedl syndrome genes.Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta.Role of vascular smooth muscle PPARγ in regulating AT1 receptor signaling and angiotensin II-dependent hypertension.Interference with peroxisome proliferator-activated receptor-γ in vascular smooth muscle causes baroreflex impairment and autonomic dysfunction.PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats.Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation.Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia.Effect of PPARγ inhibition during pregnancy on posterior cerebral artery function and structure The role of reactive oxygen species in microvascular remodeling.Genetic interference with peroxisome proliferator-activated receptor γ in smooth muscle enhances myogenic tone in the cerebrovasculature via A Rho kinase-dependent mechanism.Protecting against vascular disease in brain HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial Cells The role of oxidative stress and NADPH oxidase in cerebrovascular disease.Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ.Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.Peroxisome proliferator-activated receptor-γ protects against vascular aging.Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice.Protective Role for Tissue Inhibitor of Metalloproteinase-4, a Novel Peroxisome Proliferator-Activated Receptor-γ Target Gene, in Smooth Muscle in Deoxycorticosterone Acetate-Salt Hypertension.Interference with PPARγ in endothelium accelerates angiotensin II-induced endothelial dysfunction.The adaptation of the cerebral circulation to pregnancy: mechanisms and consequences Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle Microvascular Dysfunction and Cognitive Impairment.Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation.Context-dependent effects of SOCS3 in angiotensin II-induced vascular dysfunction and hypertension in mice: mechanisms and role of bone marrow-derived cells PPARgamma and its ligands: therapeutic implications in cardiovascular disease.Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia.Effects of the use of assisted reproduction and high-caloric diet consumption on body weight and cardiovascular health of juvenile mouse offspring PPAR-gamma agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension.Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling.Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice.Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?

P2860

Q24642728-F913D4AB-F282-4F98-B975-6EA388D7283D Q26863678-37D5F56A-F5AF-4CD9-BB5F-34C8B8D1804F Q27315042-42CF645D-61E2-4B38-8B2A-2AA73437E102 Q27342480-350A8B77-8A45-4E09-9D0A-14B9605B2C65 Q29347284-89F7CF80-4C46-4EEA-A051-923A63151DF1 Q33642053-23102873-3012-486C-A505-36DF3DA25550 Q33692662-29330D75-78B8-402E-B4DA-ED8ADDAC3B98 Q33772466-299A9166-4807-47B5-B32B-4C98EA162988 Q34046462-551B64A8-9389-48D2-AFEF-E127D124E51F Q34051403-99A6114E-3FFC-44CA-92B7-63A6D9C5F556 Q34099314-2653D846-550B-40D3-9F7D-AA53F4246219 Q34315697-DF3B7863-1393-4549-9A82-9F86E2D6F835 Q34407931-31C1E57D-D1A1-4918-871C-120108B5D85B Q34598561-B50C49A2-2505-4C4F-9A8A-93442F4DF01C Q34691864-E15FC892-188D-4DCD-BC0A-CAE08B8109A1 Q34836065-1A8DD84A-5C41-4379-B1DD-12DB6CDF216D Q34892807-6F784654-8B52-41D9-993A-6CB7F60AB65F Q34979773-1713542F-579E-4D8D-A885-28BF2467E147 Q35014033-E906055C-2590-4954-8A09-5990065B0EDA Q35118380-F3FD24BB-EF47-467A-AF16-71749981DD75 Q35169517-676AD486-79E2-4124-8739-AF6A68D0D73B Q35636191-C3312D66-51F4-46A6-AA12-CBA903823582 Q35994295-AEAA2A44-60C8-48F6-B869-F6E31E6AF05F Q36076407-72EF9283-479E-4424-82CE-5BAF75E22951 Q36372517-9F69A66C-6AA3-4BB9-991C-051B3CAD9159 Q36510633-41F28DDA-EEBC-4CB2-8515-642D6143091C Q36745113-ECE8C6F2-2368-4235-99A3-798A3936CC9E Q36837948-19EB8A57-BC4D-4384-B25F-789F8121C94D Q36839870-5236569B-CE95-4AA3-AAEE-628EFCCE0E2F Q36972995-6740FDCF-09A6-4D0B-9573-07F0B2423459 Q37034439-9188F0FB-2B2E-4189-B9FA-1544B2EB4EBE Q37139653-91EB2A45-4459-4F78-BF8F-82CD50BA9BAC Q37179467-13F99B25-1595-458E-89C4-57CF488135A7 Q37335663-4FBFBCEB-F399-47AA-9DA9-957ECB0061D1 Q37395673-F7EECF75-CAF5-4494-A9EA-BA91AF3A1C60 Q37406290-5CC39E4C-F641-47E5-A7E3-80D87DB01C8B Q37411594-CE9BB9BA-07C0-47F0-9548-FB3514310603 Q37430999-AAD9DAB0-3AD1-4FCB-9716-F3AB6AB036C1 Q37686110-6586BAD4-1A4D-4645-A65E-5F38EFA7E77C Q37686890-2F170468-17FB-45BB-9ACF-9F0647665706

P2860

Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

http://www.wikidata.org/entity/Q36692337

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Interference with PPARgamma si ...... , hypertrophy, and remodeling.

@ast

Interference with PPARgamma si ...... , hypertrophy, and remodeling.

@en

type

label

Interference with PPARgamma si ...... , hypertrophy, and remodeling.

@ast

Interference with PPARgamma si ...... , hypertrophy, and remodeling.

@en

prefLabel

Interference with PPARgamma si ...... , hypertrophy, and remodeling.

@ast

Interference with PPARgamma si ...... , hypertrophy, and remodeling.

@en

P1433

Q36692337-91FAE281-9111-4C06-9EC4-F1CB34C4AD6E

P1476

Q36692337-CB5FFAA9-3177-4588-A55C-76175EE7808D

P2093

Q36692337-1F3E3912-0954-47F7-BD70-712466B81D4B

Q36692337-20855A3E-2157-4121-AA69-96066811DFC0

Q36692337-2B256D59-745A-475C-A315-86A004B83F6F

Q36692337-38CD69E4-AC05-4F25-9D97-599FBE9A4E51

Q36692337-655B52DC-983C-4A31-A1AB-2C2E0B654624

Q36692337-7A1FA204-6454-49A4-BA8F-218A5022774F

Q36692337-B0EFA140-9104-4E4E-A99A-7601190813E5

Q36692337-B27F2D00-CE00-446E-8255-B7A427C9EE79

Q36692337-B5994C12-20D5-4615-9D95-1FA3EF201EE1

Q36692337-D19E3557-8976-41E9-8884-7D0938F7F5E6

P2860

Q36692337-00ECCF00-B668-4ED7-9370-9974690E0D22

Q36692337-0E0FBAE6-7288-439A-A4C7-7642C84A38E0

Q36692337-13EE6B3A-EFEF-4CE1-AE43-192850403BA1

Q36692337-369EB9DB-EC0D-4967-A835-3CB7A2C0D4C4

Q36692337-49E5A108-67D3-451A-8C7E-83CF4F3FC046

Q36692337-5A25B43D-DA43-4B6C-B5F4-14C8E7CEDD8B

Q36692337-5BE5D6E3-C8A0-4D48-A405-F7A38BFD01AC

Q36692337-6F3590DF-7E9A-4C12-A8A4-DBC1C5A09213

Q36692337-83C5130F-CA5D-4013-AF96-0762A03E7D65

Q36692337-8F20BDBB-F494-4BF5-9C59-23E6F765BC53

P304

Q36692337-9B54E56E-CB2A-4C19-A98B-552503C77931

P31

Q36692337-80C3EE08-C3B3-4757-BF9F-E482DE4C1B92

P356

Q36692337-DC1F3C31-57F6-4EFF-8AC1-2C66C275F1AC

P407

Q36692337-297A14B0-E287-40B3-8CCF-7ABA119258E3

P433

Q36692337-96598069-3104-4699-BEB2-695243FA7EDA

P478

Q36692337-7603A13E-E884-4FE1-B511-3F95DCE5324D

P50

Q36692337-3ABEFB05-34CD-430D-B207-7675D4870E0D

Q36692337-91D9D29C-176A-4A2F-9F1D-DAF68D87D517

P577

Q36692337-C4A0043C-4845-4E10-982C-60E774770A5C

P698

Q36692337-B3382562-42F4-4699-BDC5-6E5F37035F39

P932

Q36692337-7210D649-64E3-467A-ACEA-4E3CE520C675

P356

HYPERTENSIONAHA.107.103648

P1433

P1476

Interference with PPARgamma si ...... n, hypertrophy, and remodeling

@en

P2093

Andreas M Beyer

http://www.w3.org/2001/XMLSchema#string

Cynthia M Lynch

http://www.w3.org/2001/XMLSchema#string

Frank M Faraci

http://www.w3.org/2001/XMLSchema#string

Gary L Baumbach

http://www.w3.org/2001/XMLSchema#string

Henry L Keen

http://www.w3.org/2001/XMLSchema#string

Mary L Modrick

http://www.w3.org/2001/XMLSchema#string

Nobuyo Maeda

http://www.w3.org/2001/XMLSchema#string

Shams M Ghoneim

http://www.w3.org/2001/XMLSchema#string

Thomas D Gerhold

http://www.w3.org/2001/XMLSchema#string

Willem J de Lange

http://www.w3.org/2001/XMLSchema#string

P2860

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice

Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice

The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells.

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension.

Activation of peroxisome proliferator-activated receptor gamma by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst.

P304

867-871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HYPERTENSIONAHA.107.103648

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Curt D. Sigmund

P577

2008-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18285614

http://www.w3.org/2001/XMLSchema#string

P932

2408877

http://www.w3.org/2001/XMLSchema#string